Edwards Lifesciences Corporation
EW
$85.98
-$1.56-1.78%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.23% | -2.75% | 25.71% | -26.90% | -21.50% |
| Total Depreciation and Amortization | 35.32% | 29.64% | 36.41% | -22.61% | -19.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 427.18% | 330.81% | 205.15% | 108.71% | 18.44% |
| Change in Net Operating Assets | 66.13% | 116.40% | 19.13% | -6.69% | 33.55% |
| Cash from Operations | 55.06% | 194.15% | 26.09% | -8.22% | 65.88% |
| Capital Expenditure | -40.74% | -29.78% | 11.05% | 47.30% | 25.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 88.23% | -- | -748.26% | -748.26% | -748.26% |
| Divestitures | -98.92% | -98.92% | -- | -- | -- |
| Other Investing Activities | 83.46% | 87.03% | -1,241.24% | -867.22% | -950.76% |
| Cash from Investing | -138.16% | -130.82% | -137.58% | 600.41% | 887.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 45.41% | 20.07% | 13.90% | -26.09% | -30.14% |
| Repurchase of Common Stock | -137.06% | -464.02% | -40.58% | 59.77% | 25.96% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,056.25% | -3,445.07% | -2,703.33% | -70.49% | 447.83% |
| Cash from Financing | 11.72% | 2.67% | 35.65% | -95.03% | -194.26% |
| Foreign Exchange rate Adjustments | -130.14% | -149.72% | -92.44% | -91.76% | 104.23% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -136.53% | -106.24% | -143.56% | 167.26% | 444.47% |